Bextra - Valdecoxib - Dosage - Side Effects - Interactions - Warnings
Bextra (valdecoxib) drug information, dosage, side effects, drug interactions, and warnings. Bextra, generic drug name valdecoxib, is/was a COX-2 selective inhibitor used to treat the inflammation and pain arthritis. Bextra is now discontinued. In April 2005, the maker of Bextra voluntarily withdrew the drug from the market.
FDA Announces Changes For All NSAIDS; Bextra Withdrawn From Market
Following scrutiny of the class of arthritis drugs known as NSAIDS and COX-2 inhibitors, the FDA has taken action.
Following scrutiny of the class of arthritis drugs known as NSAIDS and COX-2 inhibitors, the FDA has taken action.
Q & A: FDA Actions On COX-2 Inhibitors & NSAIDs
On April 7, 2005, FDA announces planned regulatory actions for Bextra, Celebrex, and the non-selective prescription and over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs).
On April 7, 2005, FDA announces planned regulatory actions for Bextra, Celebrex, and the non-selective prescription and over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs).
Bextra Withdrawal - What Should You Do If You Were Taking Bextra?
You can be reimbursed for unused Bextra tablets.
You can be reimbursed for unused Bextra tablets.
Drug Monograph: Bextra / Valdecoxib
On April 7, 2005, Pfizer announced a voluntary suspension of valdecoxib from the U.S. and European Union markets. Although the cardiovascular risk of valdecoxib could not be differentiated from other NSAIDs, the FDA has concluded that the additional, increased risk of rare but serious skin reactions associated with valdecoxib warrants its withdrawal from the market.
On April 7, 2005, Pfizer announced a voluntary suspension of valdecoxib from the U.S. and European Union markets. Although the cardiovascular risk of valdecoxib could not be differentiated from other NSAIDs, the FDA has concluded that the additional, increased risk of rare but serious skin reactions associated with valdecoxib warrants its withdrawal from the market.
Patient Education: Bextra / Valdecoxib Tablets
Patient education for Bextra / valdecoxib tablets. This drug is discontinued in the United States. Patients taking Valdecoxib should contact their prescriber regarding discontinuation and alternative therapies.
Patient education for Bextra / valdecoxib tablets. This drug is discontinued in the United States. Patients taking Valdecoxib should contact their prescriber regarding discontinuation and alternative therapies.
Product Photographs: Bextra / Valdecoxib Tablets
Product photographs of Bextra / valdecoxib tablets.
Product photographs of Bextra / valdecoxib tablets.
Bextra History: How To Take Bextra For Arthritis
Bextra, like Celebrex and Vioxx, is a COX-2 specific inhibitor prescribed for the relief of pain, inflammation, and stiffness associated with osteoarthritis and rheumatoid arthritis. What should you know if you take Bextra?
Bextra, like Celebrex and Vioxx, is a COX-2 specific inhibitor prescribed for the relief of pain, inflammation, and stiffness associated with osteoarthritis and rheumatoid arthritis. What should you know if you take Bextra?
11/08/2004 Bextra History: Pfizer Calls Bextra Study Unsubstantiated
11/08/2004, Pfizer called a new study about Bextra which cites an increased heart risk, reported at an American Heart Association meeting and in the New York Times, "unsubstantiated".
11/08/2004, Pfizer called a new study about Bextra which cites an increased heart risk, reported at an American Heart Association meeting and in the New York Times, "unsubstantiated".
11/13/2002 Bextra History: FDA Issues Warning About Bextra
11/13/2002, The FDA issued warnings and product label changes for the drug Bextra (valdecoxib), based on postmarketing adverse reports.
11/13/2002, The FDA issued warnings and product label changes for the drug Bextra (valdecoxib), based on postmarketing adverse reports.
11/19/2001 Bextra History: FDA Approves Bextra (Valdecoxib)
11/19/2001, the FDA approved Bextra (valdecoxib) for the treatment of signs and symptoms of osteoarthritis and adult rheumatoid arthritis, and the pain associated with menstrual cramping.
11/19/2001, the FDA approved Bextra (valdecoxib) for the treatment of signs and symptoms of osteoarthritis and adult rheumatoid arthritis, and the pain associated with menstrual cramping.
03/24/2001 Bextra History: FDA Asked To Approve Valdecoxib
On March 23, 2001, it was announced that Pharmacia has submitted a new drug application to the FDA (U.S. Food and Drug Administration) for approval of Valdecoxib, a second generation version of Celebrex.
On March 23, 2001, it was announced that Pharmacia has submitted a new drug application to the FDA (U.S. Food and Drug Administration) for approval of Valdecoxib, a second generation version of Celebrex.